|
US5478745A
(en)
|
1992-12-04 |
1995-12-26 |
University Of Pittsburgh |
Recombinant viral vector system
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
FR2711523B1
(fr)
|
1993-10-26 |
1996-02-16 |
Transgene Sa |
Procédé de préparation d'un aérosol viral.
|
|
EP0745134A1
(en)
|
1994-02-22 |
1996-12-04 |
Danafarber Cancer Institute |
Nucleic acid delivery system, method of synthesis and uses thereof
|
|
US5837520A
(en)
|
1995-03-07 |
1998-11-17 |
Canji, Inc. |
Method of purification of viral vectors
|
|
FR2737222B1
(fr)
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
IL127692A0
(en)
|
1996-07-01 |
1999-10-28 |
Rhone Poulenc Rorer Sa |
Method for producing recombinant adenovirus
|
|
WO1998022588A2
(en)
|
1996-11-20 |
1998-05-28 |
Introgen Therapeutics, Inc. |
An improved method for the production and purification of adenoviral vectors
|
|
AU5370598A
(en)
|
1996-12-13 |
1998-07-03 |
Schering Corporation |
Methods for purifying viruses
|
|
FR2763958A1
(fr)
|
1997-05-29 |
1998-12-04 |
Transgene Sa |
Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
|
|
CA2242035C
(en)
|
1997-07-01 |
2004-11-23 |
Transgene S.A. |
Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
|
|
AU752658B2
(en)
|
1998-05-06 |
2002-09-26 |
Association Francaise Contre Les Myopathies |
Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
|
|
JP3864610B2
(ja)
|
1998-05-21 |
2007-01-10 |
旭硝子株式会社 |
水分散型撥水撥油剤組成物およびその製造方法
|
|
EP0998945A1
(en)
|
1998-09-30 |
2000-05-10 |
Transgene S.A. |
Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
|
|
NZ512504A
(en)
|
1998-12-31 |
2004-01-30 |
Aventis Pharma Sa |
Method for separating viral particles
|
|
JP4802366B2
(ja)
|
1999-02-22 |
2011-10-26 |
トランスジェン・ソシエテ・アノニム |
精製ウイルス調製物の取得方法
|
|
EP1156832A1
(en)
|
1999-12-28 |
2001-11-28 |
Transgene S.A. |
Use of lithium (li?+ ) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
|
|
CA2881743A1
(en)
|
2002-09-25 |
2004-04-08 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
ATE443765T1
(de)
|
2003-03-21 |
2009-10-15 |
Santaris Pharma As |
Analoga kurzer interferierender rna (sirna)
|
|
ATE500267T1
(de)
|
2003-07-21 |
2011-03-15 |
Transgene Sa |
Multifunktionelle cytokine
|
|
WO2005073378A1
(en)
|
2004-01-30 |
2005-08-11 |
Santaris Pharma A/S |
MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
|
|
US7361468B2
(en)
*
|
2004-07-02 |
2008-04-22 |
Affymetrix, Inc. |
Methods for genotyping polymorphisms in humans
|
|
US20080213891A1
(en)
|
2004-07-21 |
2008-09-04 |
Alnylam Pharmaceuticals, Inc. |
RNAi Agents Comprising Universal Nucleobases
|
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
|
WO2007124452A2
(en)
|
2006-04-20 |
2007-11-01 |
The Regents Of The University Of California |
Methods for expressing multiple sirna and shrna from a single vector
|
|
WO2010030396A2
(en)
|
2008-09-15 |
2010-03-18 |
Stanford University |
Novel shrna gene therapy for treatment of ischemic heart disease
|
|
WO2011111072A2
(en)
|
2010-03-10 |
2011-09-15 |
Transgene Biotek Ltd. |
Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer
|
|
US9163236B2
(en)
|
2010-12-06 |
2015-10-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Pharmaceutical composition comprising NANOG SHRNA, and method of using NANOG SHRNA to treat cancer
|
|
JP6188728B2
(ja)
*
|
2012-02-07 |
2017-08-30 |
グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
核酸送達の区画化方法ならびにその組成物および使用
|
|
US20130259927A1
(en)
|
2012-04-02 |
2013-10-03 |
Gradalis, Inc. |
Ewing's Sarcoma Bifunctional shRNA Design
|
|
WO2014004572A2
(en)
*
|
2012-06-25 |
2014-01-03 |
Isis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
|
EP2872183B1
(en)
|
2012-07-11 |
2018-09-26 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated gene therapy for rpgr x-linked retinal degeneration
|
|
WO2014052855A1
(en)
|
2012-09-27 |
2014-04-03 |
Population Diagnostics, Inc. |
Methods and compositions for screening and treating developmental disorders
|
|
CA2933554A1
(en)
*
|
2013-12-12 |
2015-06-18 |
The Brigham And Women's Hospital, Inc. |
Treating neurodegenerative disease
|
|
US10400243B2
(en)
*
|
2014-11-25 |
2019-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of UBE3A-ATS expression
|
|
LT3374509T
(lt)
*
|
2015-11-12 |
2021-03-10 |
F. Hoffmann-La Roche Ag |
Oligonukleotidai, skirti sukelti iš tėvo paveldėto ube3a raišką
|
|
US20190224339A1
(en)
|
2016-04-29 |
2019-07-25 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2020051417A2
(en)
|
2018-09-07 |
2020-03-12 |
The Chemours Company Fc, Llc |
Fluorine removal from antimony fluorohalide catalyst using chlorocarbons
|
|
WO2020061528A1
(en)
|
2018-09-21 |
2020-03-26 |
University Of Connecticut |
Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
|